Lexaria Bioscience Terminates Material Agreement
Ticker: LEXX · Form: 8-K · Filed: Sep 25, 2025
Sentiment: neutral
Topics: material-agreement-termination, corporate-action
Related Tickers: LXRP
TL;DR
Lexaria terminated a big deal, details TBD.
AI Summary
Lexaria Bioscience Corp. filed an 8-K on September 25, 2025, reporting the termination of a material definitive agreement as of September 19, 2025. The filing does not specify the counterparty or the nature of the agreement, only that it was deemed material and has now been terminated.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, financial standing, and future strategic direction.
Risk Assessment
Risk Level: medium — Termination of a material agreement introduces uncertainty regarding the company's business relationships and financial stability.
Key Players & Entities
- Lexaria Bioscience Corp. (company) — Registrant
- September 19, 2025 (date) — Date of earliest event reported
- September 25, 2025 (date) — Filing date
FAQ
What was the specific material definitive agreement that was terminated?
The filing does not specify the name or details of the material definitive agreement that was terminated.
Who was the counterparty to the terminated agreement?
The filing does not disclose the identity of the other party involved in the terminated agreement.
What is the effective date of the termination?
The termination was effective as of September 19, 2025.
What are the potential financial or operational impacts of this termination on Lexaria Bioscience Corp.?
The filing does not detail the specific impacts, but the termination of a material agreement generally carries significant financial and operational implications.
Does this termination relate to any specific product or business segment of Lexaria Bioscience Corp.?
The filing does not provide information linking the terminated agreement to any specific product or business segment.
Filing Stats: 526 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2025-09-25 17:14:47
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share Warrants to Purchase Common
- $5,000,000 — ssue and sell, from time to time, up to $5,000,000 in aggregate principal amount of shares
- $38,236.00 — e Sales Agreement for gross proceeds of $38,236.00. 2 SIGNATURES Pursuant to the requi
Filing Documents
- lxrp_8k.htm (8-K) — 24KB
- 0001640334-25-001717.txt ( ) — 153KB
- lxrp-20250919.xsd (EX-101.SCH) — 5KB
- lxrp-20250919_lab.xml (EX-101.LAB) — 16KB
- lxrp-20250919_cal.xml (EX-101.CAL) — 1KB
- lxrp-20250919_pre.xml (EX-101.PRE) — 12KB
- lxrp-20250919_def.xml (EX-101.DEF) — 6KB
- lxrp_8k_htm.xml (XML) — 5KB
02 Termination of a Material Definitive Agreement
Item 1.02 Termination of a Material Definitive Agreement. Effective September 19, 2025, Lexaria Bioscience Corp. (the "Company") terminated the Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC (the "Agent"), as originally entered into on August 21, 2024 (the full text having been filed as Exhibit 1.1 to the Company's Current Report on Form 8-K filed August 22, 2024) and, as amended by Amendment No. 1 on February 5, 2025 (the full text having been filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed February 5, 2025) collectively the "Sales Agreement". The Sales Agreement provided that the Company may issue and sell, from time to time, up to $5,000,000 in aggregate principal amount of shares (the "Shares") of the Company's common stock through or to the Agent, as the Company's sales agent or principal. As at the date of termination, the Company had sold an aggregate 14,995 Shares under the Sales Agreement for gross proceeds of $38,236.00. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 25, 2025 LEXARIA BIOSCIENCE CORP. /s/ Richard Christopher Name: Richard Christopher Title: Chief Executive Officer 3